亚洲精品国产成人一区二区_欧美性xxxxx极品娇小_国产欧美久久一区二区三区_日日麻批免费40分钟无码

Mabwell's Innovative Drug 6MW3511 Injection is Approved for Clinical Trial

Release time:Aug 23, 2022

Mabwell (stock code: 688062.SH), an innovative biopharmaceutical company with the layout of the whole industry chain, announced today that the IND application for the self-developed 6MW3511 injection has been formally approved by the Center for Drug Evaluation (CDE) of China National Medical Products Administration for clinical trial in advanced solid tumor.

6MW3511 is a bifunctional group drug protein independently constructed by Mabwell using humanized anti-PD-L1 nanobodies to link to TGF-β RII mutants. The mutant design facilitates the maintenance of whole-molecule stability and reduces degradation of the natural TGF-β group during the manufacture process and in vivo. By blocking PD-1/PD-L1 and TGF-β/TGF-β-R dual pathways simultaneously, and with the excellent local tumor penetrability resulting from the concise structure, 6MW3511 is expected to further address the difficult problem of immunosuppression in the tumor microenvironment. The results of preclinical studies showed that 6MW3511 injection had good in vivo anti-tumor efficacy and good tolerability in animals.

主站蜘蛛池模板: 辽宁省| 九江县| 鄂温| 吉安市| 双柏县| 色达县| 英德市| 华容县| 靖宇县| 乌兰县| 察隅县| 西宁市| 故城县| 肇庆市| 乐清市| 永丰县| 宁海县| 华亭县| 垣曲县| 嘉黎县| 三穗县| 县级市| 临泉县| 宜都市| 金川县| 银川市| 白山市| 吉安县| 荆门市| 宣威市| 塘沽区| 南投市| 易门县| 凤山市| 施秉县| 华亭县| 绥德县| 白玉县| 小金县| 天镇县| 罗山县|